Physicians' Academy for Cardiovascular Education

test - SGLT2 inhibitor benefits younger, overweight, poorly controlled T2DM patients

SGLT2 inhibitor benefits younger, overweight, poorly controlled T2DM patients

Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials

Literature - Romera I et al., J Diabetes Complications. 2016 - J Diabetes Complications. 2016; published online ahead of print

Main results

Adjusted mean change from baseline in body weight reduction at week 24 was −1.61 kg (95%CI: −2.16 to −1.05; P<0.001) for empagliflozin 10mg vs. placebo, and −1.81 kg (95% CI: −2.38 to −1.24; P<0.001) for empagliflozin 25mg vs. placebo.

Conclusion

In T2DM patients younger than 65 years, with BMI 25–35 kg/m2 and poorly controlled HbA1c levels (≥64 mmol/mol), the addition of empagliflozin to oral standard therapies was associated with a clinically and statistically significant reduction in HbA1c and in body weight compared to placebo, with a favourable safety profile. These data support an added benefit of the use of empagliflozin on top of standard therapy in this patient group.

References

Show references

Find this article online at J Diabetes Complications

Share this page with your colleagues and friends: